Search Results
Oct 22, 2025, 16:05 ET Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
achieved following weekly subcutaneous dosing. This trial is a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2). All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Participants will subsequently transition
More news about: Viking Therapeutics, Inc.
Oct 22, 2025, 12:29 ET Surgeons: Obesity Isn't About Willpower -- It's a Treatable Medical Condition
U.S. Centers for Disease Control and Prevention defines obesity as having a body mass index (BMI) of 30 or higher, and severe obesity as a BMI of 40 or higher. Reframing Obesity as a Health Condition
More news about: American College of Surgeons
Oct 21, 2025, 16:01 ET Can Ozempic Slow Aging? New Study Raises Hope
system aging improved by approximately 4–5 years. Beyond Weight Loss: Analysis controlled for BMI, indicating benefits beyond semaglutide's known effect of visceral fat reduction. Predictive Insights:
More news about: TruDiagnostic
Oct 21, 2025, 11:00 ET RunStar® Expands Smart Scale Lineup With Three New Models Designed for Personalized Health Tracking
fat, including a breakdown of subcutaneous versus visceral fatMuscle mass, showing how much of the body's weight comes from muscleBMI, providing a general indicator of body composition based on height and weight
More news about: RunStar
Oct 21, 2025, 07:05 ET Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
The VANQUISH-1 study is targeting enrollment of approximately 4,500 adults who do not have type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is targeting enrollment of approximately
More news about: Viking Therapeutics, Inc.
Oct 20, 2025, 14:31 ET Sōlaria Biō Announces New Bone Health Breakthrough with Bondia™
286 postmenopausal women and found that daily consumption of Bondia™ significantly slowed bone loss compared to placebo in women with osteopenia or a BMI greater than/equal to 30. "For decades, treatment options for bone loss have been limited, especially for women with early-stage
More news about: Sōlaria Biō
Oct 20, 2025, 09:00 ET SHEIN and Rap Superstar GloRilla Drop Fire-and-Ice-Inspired Collection Built for Self-Expression
her the title of Hottest Female Rapper of 2024. This year GloRilla became the youngest female artist to receive Songwriter of the Year at the BMI R&B/Hip-Hop Awards, further cementing her status as one of the premier artists of today.
More news about: SHEIN
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET CITY OF LONDON INVESTMENT GROUP PLC ("City of London" or "the Group" or "the Company" or "CLIG") TRADING UPDATE FOR THE QUARTER TO 30 SEPTEMBER 2025
presented as net of fee performance figures. The CLIM Global Emerging Markets strategy is shown against the S&P Emerging Frontier Super Composite BMI Net TR Index, the CLIM Global Developed CEF International Equity Strategy is shown against the MSCI ACWI ex-US Net TR Index, the CLIM Opportunistic Value
More news about: City of London Investment Group PLC
Oct 19, 2025, 20:10 ET 歌禮完成小分子GLP-1R激動劑ASC30治療肥胖症的每月一次皮下儲庫型治療制劑的美國IIa期研究受試者入組
ASC30每月一次皮下儲庫型治療制劑的IIa期研究是一項在美國開展的、為期 12 周、隨機、雙盲、安慰劑對照及多中心的臨床研究，旨在評估其在肥胖受試者（體重指數（BMI）≥ 30 kg/m2）或伴有至少一種體重相關合併症的超重受試者（27 kg/m2 ≤ BMI < 30 kg/m2）中的安全性、耐受性和療效。該研究分為不同劑量的三個隊列，共計65名受試者。預計將於2026年第一季度獲得頂線數據。 Ib期研究（
More news about: 歌禮製藥有限公司
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
multi-center study conducted in the U.S. to evaluate the safety, tolerability and efficacy in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. The study consists of three cohorts
More news about: Ascletis Pharma Inc.
Oct 16, 2025, 08:00 ET Beyond GLP-1s: Withings Health Solutions Unveils Best Practices for Obesity Care Management Programs
coordinated care, and improved outcomes across obesity and comorbidities. Clinical Rigor: Traditional BMI measurements often miss critical factors like fat distribution, muscle mass, and metabolic health, leading to misdiagnosis and care disparities.
More news about: Withings Health Solutions
Oct 16, 2025, 06:12 ET The Galien Foundation Hosts 2025 Patient Summit to Amplify the Patient Voice in Healthcare
Global Head of Regenerative Beauty at L'Oréal Groupe 10:50 – 11:50am PANEL 3 Beyond BMI: Precision Obesity Care Keri Hildick – Chair,
More news about: The Galien Foundation
Oct 15, 2025, 06:45 ET Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
non-inferior in A1C reduction from baseline after 40 weeks, compared to dapagliflozin. Study participants had an A1C between ≥7.0% and ≤10.5% and a BMI of ≥23 kg/m2. Participants randomized to orforglipron initiated treatment with 1 mg once daily and increased the dose every four weeks until
More news about: Eli Lilly and Company
Oct 09, 2025, 10:05 ET Vytala™ Announces New Clinical Data and IRB Approval for Seracal™
NIH clinical trial, Lym-X-Sorb generated statistically significant improvements in BMI, fat-soluble vitamin absorption, and overall tolerance in subjects with cystic fibrosis and exocrine pancreatic insufficiency. Vytala licensed exclusive
More news about: Vytala
Oct 08, 2025, 11:11 ET BMI Heads to Albuquerque to Showcase Digital Solutions for the ARSL Conference 2025
affordable." BMI looks forward to supporting the preservation projects discussed in Albuquerque and helping more rural and small libraries safeguard local stories for future generations. About BMIEstablished in 1958 as Bay
More news about: BMI Imaging Systems, Inc.
Oct 07, 2025, 08:00 ET HealthVerity announces taXonomy Pathways: Closing evidence gaps with the most comprehensive patient journeys
including physician notes, that fundamentally enrich the patient journey. In diabetes and obesity cohorts, repeated measures such as BMI, HbA1c, weight, blood pressure and lipid panels provide a comprehensive view of disease progression and treatment response. For heart failure, echocardiogram‑derived
More news about: HealthVerity, Inc.
Oct 03, 2025, 08:00 ET Twin Health Outperforms Traditional Care & Legacy Digital Health Solutions, Setting New Standard for Diabetes and Weight Loss
most programs that are paid for based on participation, Twin Health is paid based on measurable clinical and financial outcomes, such as improved A1C, BMI, and medication elimination, aligning its incentives directly with employers and health plans. Backed by the Validation Institute's $100,000 ERISA Guarantee,
More news about: Twin Health
Oct 02, 2025, 09:10 ET Amber Premium Added to S&P Global Broad Market Index (BMI)
S&P Global Broad Market Index (BMI), effective Monday, September 22, 2025. Inclusion in the S&P Global BMI is a notable progress for Amber Premium, reflecting the company's growing prominence on the global stage. The S&P Global BMI stands as one of the global indexes
More news about: Amber International Holding Limited
Oct 01, 2025, 12:00 ET BMI Imaging Highlights Launch of Digital Vault: A Verifiable, Long-Term Records Platform
to demonstrate reliability and compliance. About BMIEstablished in 1958 as Bay Microfilm Incorporated, BMI Imaging Systems embarked on a mission to assist County Recorders with archiving land records on microfilm. By the 1960s,
More news about: BMI Imaging Systems, Inc.
Oct 01, 2025, 10:30 ET Kidney Transplant Market Size to Reach US$ 42.8 Bn by 2033, Driven by Advancements in Therapies and Rising CKD Cases
infections in kidney transplant patients, aiming to enhance post-transplant recovery and reduce related risks. In August 2025, BMI OrganBank earned FDA Breakthrough Device Designation for its kidney preservation device, which improves donor organ assessment, preservation quality,
More news about: DataM Intelligence 4 Market Research LLP
Sep 30, 2025, 10:50 ET Dialysis Equipment Market to Reach US$ 19.14 billion by 2031 at CAGR of 5.9% | Business Market Insights
NEW YORK, Sept. 30, 2025 /PRNewswire/ -- As per the latest market research by Business Market Insights (BMI), the research report "Dialysis Equipment Market Size and Forecast (2021–2031)" forecasts how the market is set to surge 49% by 2031 as Growing Cases
More news about: Business Market Insights
Sep 30, 2025, 10:30 ET Pressure Monitoring Devices Market Outlook: Increasing Remote Patient Monitoring to Drive Market Growth to US$26.6 Billion by 2033 | Business Market Insights
NEW YORK, Sept. 30, 2025 /PRNewswire/ -- As per the latest market research by Business Market Insights (BMI), the research report "Pressure Monitoring Devices Market Outlook Size and Forecast (2022–2033)" forecasts how the market is set to surge 56% by 2033
More news about: Business Market Insights
Sep 30, 2025, 10:15 ET Joint Reconstruction Devices Market Reach US$ 30,573.75 Million by 2033 at CAGR of 5.0% | Business Market Insights
NEW YORK, Sept. 30, 2025 /PRNewswire/ -- As per the latest market research by Business Market Insights (BMI), the research report "Joint Reconstruction Devices Market Size and Forecast (2021–2031)" forecasts how the market is set to surge 54.01% by 2033 as
More news about: Business Market Insights